Search Immortality Topics:

Page 10«..9101112..2030..»

Assessing biotechnology in the age of cloud computing – Cloud Tech

Posted: March 21, 2017 at 6:46 pm

In order to ensure that patient outcomes are constantly being improved upon it is important that the speed of change within the biotechnology sector occurs at an exponential rate. However, this continued drive for innovation puts immense pressure on IT departments to develop new technologies at speed, while also making sure that they do this cost effectively.

Add to this the fact that, more so than other industries, biotech firms are extremely tightly regulated. As a result, IT groups within this industry are often reluctant to introduce more complexity into what is already a very complex environment. To them, expanding a data centre can often feel a whole lot easier than navigating the regulations of the cloud. Despite this, growth in the demand for cloud computing in life sciences research and development is escalating due to the benefits it brings to the industry benefits like exceeding regulatory requirements, for example.

At iland, we have worked with many companies in the healthcare, life sciences and biotech industries. Therefore, we know from experience that the implementation of cloud computing in biotechnology empowers organisations with the control and flexibility needed to lead the way in both the research world as well as the businesses world. For example, we recently worked with a US based biotechnology organisation on their backup and disaster recovery (DR) strategy, and were able to drive global data centre consolidation with host-based replication to the iland cloud. As a result, their DR testing and auditing processes were greatly simplified and streamlined which drove significant cost savings as well as compliance assurance.

If you still need convincing here are three key benefits that we believe cloud brings to biotech organisations:

When the Human Genome Project began it was one of the most extensive research projects in the field to date costing billions of pounds and lasting over a decade. These days, thanks largely to cloud technology, it can bedone in just 26 hours. Things such as drug R&D, clinical research as well as a whole host of other areas have benefited just as much from the rapid growth of computational power. The better your technology is at crunching huge sets of data, the quicker you can innovate.

Cloud computing within the biotech sector can take big data analysis to the next level by means of performance, connectivity, on-demand infrastructure and flexible provisioning. Labs can also benefit from immense computing power without the cost and complexity of running big onsite server rooms. They can also scale up at will in order to make use of new research and ideas almost instantly.

Concerns have been voiced that so called scientific computing in the cloud may make results less reproducible. One concern is that cloud computing will be a computing ‘black box’ that obscures details needed to accurately interpret the results of computational analyses. In actual fact, by leveraging the application program interfaces (APIs) in the iland cloud, biotech customers are able to integrate cloud data back into on-premises IT systems to ensure that data analyses done in the cloud can be easily shared and consumed by other applications. Essentially, cloud computing services bring more players to the table to solve the giant puzzle. Its a win-win situation from an economic and patient standpoint, and several big name companies are jumping on the biotech cloud bandwagon.

Biotech companies need to maintain strong access and authentication controls, while also being able to collaborate easily.For this reason audit trails and other measures are often required to verify that information has not been improperly altered, and that good experimental and manufacturing procedures have been followed. At the same time biotechnologists need to be able to access and share data across multiple departments or even multiple companies.

Cloud computing in biotechnology makes this all possible. Theiland cloud, for instance, centralises data, ensuring security and data sovereignty while facilitating collaboration. It supports extensive user and role based access control, two-factor authentication and integrity monitoring to prevent improper access and changes. In addition to data encryption, vulnerability scanning and intrusion detection, these measures facilitate security and compliance, without disrupting the internal workflow.

Complex regulatory requirements and logistics combined with niche markets make efficiency paramount within biotechnology. Even minor mistakes as a result of sloppy process management can easily result in major issues. Real-time operational reporting dramatically improves efficiency, quality control and decision making, allowing organisations to react instantly to challenges and opportunities, both internal and external.

As well as enhanced billing visibility and resource management functions, the release of our latest Secure Cloud Services means that the iland cloud now includes on-demand security and compliance reports. This advanced cloud management functionality is designed to foster strategic, self-sufficient control of a cloud environment, optimising overall cloud usage and costs to drive business initiatives and growth.

Without a shadow of a doubt, cloud technology can help biotechnology companies build the future.From research and development to marketing, computing affects everything your organisation does. With rich experience in the biotech, healthcare and life sciences sector, you should talk to iland today to find out how our cloud hosting services can give you the power to develop at the speed of thought, not the speed of compliance or processing.

Read more: Why the cloud could hold the cure to diseases

Read the original:
Assessing biotechnology in the age of cloud computing – Cloud Tech

Recommendation and review posted by Guinevere Smith

Vacancies at AIIMS, Jodhpur for 48 Junior Resident and Tutor/Demonstrator (Biochemistry) Posts – Jagran Josh

Posted: March 21, 2017 at 6:45 pm

All India Institute of Medical Sciences, Jodhpur Jobs Notification: All India Institute of Medical Sciences, Jodhpur invited applications for the post of Junior Resident (Clinical) and Tutor/Demonstrator (Biochemistry) Posts. The eligible candidates can apply to the post through the prescribed format and walk in interview on 28 March 2017.

Junior Resident (Clinical) candidates must possess MBBS from the MCI recognized Institute. The Candidate must have compulsory rotatory internship and must produce internship completion certificate

Tutor/Demonstrator (Biochemistry) candidates must possess MBBS from the MCI recognized Institute or M.Sc. in Biochemistry. The Candidate must have compulsory rotatory internship and must produce internship completion certificate for MBBS Candidates

Eligible candidates can apply to the post through the prescribed format and walk in interview on 28 March 2017at 10:00am at Medical College of AIIMS, Jodhpur (Rajasthan).

Official Notification

Vacancy Summary

Notification details

Notification No. :Admn/Estt/01/JR/2017-AIIMS.JDH

Important Date:

Walk in interview – 28 March 2017 at 10:00

Age Limit Junior Resident (Clinical) and Tutor/Demonstrator (Biochemistry) Posts- 30 Years

Selection Procedure forJunior Resident (Clinical) and Tutor/Demonstrator (Biochemistry) PostsJob

The selection will be on the basis of the interview. The list of selected candidates will be uploaded on website. Candidates are advised to check the Institute website regularly for information

Application Fees for Junior Resident (Clinical) and Tutor/Demonstrator (Biochemistry) Posts

Gen & OBC : Rs.1000/-


Women Candidates: NIL

Official Website

2000+ Govt Jobs Closing by 26 March; Group C & D Posts in Air Force, Vyapam, Custom Department, PSC

Top Government Jobs announced in March 2017; 4300+ Vacancies in Central and State Govt. Departments

3000+ Jobs for 10th Pass: Vacancy in GSSSB, Delhi Cantt, Intelligence Bureau, Air Force, etc.

Employment News 18-24 March 2017: Major Jobs Available at CRPF, Air Force, Canara Bank and other

Get the latest Sarkari Naukri notification and find study materials, study tips and practice paper sets for Sarkari Naukri exams


View original post here:
Vacancies at AIIMS, Jodhpur for 48 Junior Resident and Tutor/Demonstrator (Biochemistry) Posts – Jagran Josh

Recommendation and review posted by Fredricko

Research spotlights early signs of disease using infrared light: New research – Science Daily

Posted: March 21, 2017 at 6:45 pm

Research spotlights early signs of disease using infrared light: New research
Science Daily
Produced from the cell membranes of mammals, microvesicles play a role in cell communication and carry a "cargo" of RNA, DNA, proteins, lipids and other biomolecules that they use to dramatically change the biochemistry of other cells. Microvesicles

and more »

Original post:
Research spotlights early signs of disease using infrared light: New research – Science Daily

Recommendation and review posted by Fredricko

How Many More Seasons Does Grey’s Anatomy Have Left In It? Ellen Pompeo Says… – E! Online

Posted: March 21, 2017 at 6:45 pm

When Grey’s Anatomy returns for its already-ordered 14th season this fall, it will not only air its 300th (!!) episode, but it’ll finally tie classic sitcom The Adventures of Ozzie and Harriet for ABC’s longest-running series ever. (And unlike that other show, Shonda Rhimes and Co. show no signs of slowing down!) In this day and age of Peak TV, for any series to even come close to a milestone like this is a damn near miracleand the cast knows it.

“It’s been perfect to be able to have a job that you can go to,” OG Grey’s cast member Justin Chambers told E! News on the red carpet at the PaleyFest event honoring the series. “Just having a routine and working with people that you love and enjoying your character. To be able to say that you’ve been on a show this longit’s a great gig to be able to say that.”

Chandra Wilson, who’s been there since day one alongside Chambers, couldn’t help but agree. “I’ll tell you, as an actor, the opportunity to be involved in something historic is amazing, so I love that,” she gushed. “These characters and this show are cemented in history, so to know that little contribution is thereand it will always bethat’s amazing. So it’s a great honor.”

Kevin McKidd, who joined the series five years into its run, couldn’t be more thankful for getting the opportunity to be a part of Grey’s Anatomy. “I pinch myself every single day that I’m part of it,” he admitted. “It’s unbelievable. I really feel honored and deeply grateful that I’m part of a thing that’s actually making a piece of history. It’s a really exciting thing and not to be taken lightly. These things don’t happen often.”

So, how much longer do Ellen Pompeo and her co-stars think they have left in them? Do they dare dream of giving Gunsmoke’s record 20 seasons a run for their money in order to become TV’s longest running live-action series ever?

“I don’t know. I know that we want to try to,” the leading lady herself admitted before stopping herself short. “Well, let’s just see, you know? I don’t like to take things for granted. You can’t just assume the show can go on forever. It’s up to the fans. And the fans will let us know how long they want the show to air.”

In that case, she may want to settle in for the long haul, because if it’s up to the fans, Grey’s Anatomy isn’t going anywhere anytime soon.

For more from Pompeo and her co-stars, be sure to check out the videos above.

Grey’s Anatomy airs Thursdays at 8 p.m. on ABC.

Read more:
How Many More Seasons Does Grey’s Anatomy Have Left In It? Ellen Pompeo Says… – E! Online

Recommendation and review posted by Guinevere Smith

Sarah Drew: Jackson and April Will "Always Be Each Other’s ‘Person’" – POPSUGAR

Posted: March 21, 2017 at 6:45 pm

Sarah Drew: Jackson and April Will "Always Be Each Other's 'Person'"
Jackson and April have made a breakthrough on Grey's Anatomy. After all their ups and downs, all it takes is a trip to Montana to rekindle everything they had before. We had a feeling things would go this way when Sarah Drew spoke about the episode
Sarah Drew Asked Grey's Anatomy to Include a Breast Pump Scene, and We're All for ItGlamour
22 Things We Learned From the 'Grey's Anatomy' PaleyFest PanelWetpaint
Grey's Anatomy Round Table: Will What Happened In Montana, Stay in Montana?TV Fanatic

all 5 news articles »

See original here:
Sarah Drew: Jackson and April Will "Always Be Each Other’s ‘Person’" – POPSUGAR

Recommendation and review posted by Fredricko

Anatomy Of A Decision, Part 2: The Newsroom – Benzinga

Posted: March 21, 2017 at 6:45 pm

Professional expert network GLG has produced a new series of videos focused on decision making in the business world. As part of the series, GLG, the world’s leading membership network for professional learning, has interviewed a number of business leaders to ask about what considerations go into making important decisions.

In this installment, GLG speaks with former New York Times executive editor Jill Abramson about her decision-making process in the newsroom.

Abramson said her background as an investigative journalist in Washington helped prepare her for the role of executive editor.

When you have to confront powerful people about unpleasant things that they dont want to talk about like their personal finances or their campaign finances, you develop a kind of calm steadiness that allows you not to get horribly nervous, Abramson explained.

Abramson discussed at length possibly the most difficult and important leadership decision she had to make during her career. Back in 2013, Times reporter Eric Schmidt was working on a story about an intercepted conversation between Al-Qaeda leaders that led the United States to raise the terror alert level at the time. Abramson received a phone call from the director of national intelligence, who told her that the New York Times would have blood on its hands if they chose to publish the story.

Abramson emphasized the importance of communication and placing trust in her team.

I spoke at length with Eric. It was very important to me. He was closest the reporter is always closest to the story, she said.

In talking to him, I really felt that we could go ahead and publish the story, but that Eric and I agreed we could withhold the details that it was Zawahiri and someone in Yemen. The story had other valuable information to explain this higher terror alert to our readers but that those details, while obviously its the leader of Al-Qaeda, are newsworthy, they might not be essential to the reader understanding the contours of the story.

Abramson said the media is constantly facing the difficult decision of addressing national security or law enforcement issues that could potentially compromise ongoing investigations and put people in danger.

Its really a balancing test, and theres no perfect formula for it, where you weigh the urgency of the story and is it important for the public to know, and if it is, to balance that against the seriousness of the request and the sensitivity of the story that it might cause actual harm, she concluded.

While Abramson said the top responsibility of any journalists is to keep the public informed, sensitive information comes with a heavy burden of responsibility when peoples lives may be at risk.

Related Link:

Anatomy Of A Decision, Part 1: The C-Suite _______ Image Credit: “New York Times Newsroom” By Bpaulh (Own work (Original text: self-made)) [Public domain], via Wikimedia Commons

Posted-In: Al-Qaeda GLG Jill Abramson New York TimesNews Management Media Interview Best of Benzinga

2017 Benzinga does not provide investment advice. All rights reserved.

Follow this link:
Anatomy Of A Decision, Part 2: The Newsroom – Benzinga

Recommendation and review posted by Guinevere Smith

Page 10«..9101112..2030..»